A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

This publication has 22 references indexed in Scilit:

• Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group
  Journal of Clinical Oncology, 2008
• Cancer Statistics, 2008
  CA: A Cancer Journal for Clinicians, 2008
• Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2006
• Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood
  Lung Cancer, 2006
• Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2005
• AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer
  Cancer Research, 2005
• Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2004
• The biology of VEGF and its receptors
  Nature Medicine, 2003
• Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2002
• Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
  Journal of Clinical Oncology, 2000